Virtu Financial’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Virtu Financial’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-13,098	Closed	-$17K	–	2248
2023 Q3	$17K	Buy	+13,098	New	+$11.4K	﹤0.01%	1040
2023 Q2	–	Sell	-32,386	Closed	-$14K	–	2309
2023 Q1	$14K	Buy	+32,386	New	+$17.1K	﹤0.01%	1313
2022 Q4	–	Sell	-14,812	Closed	-$11K	–	2361
2022 Q3	$11K	Buy	+14,812	New	+$16.8K	﹤0.01%	1514
2019 Q4	–	Sell	-22,425	Closed	-$170K	–	1960
2019 Q3	$170K	Buy	+22,425	New	+$253K	0.01%	1000
2019 Q2	–	Sell	-22,384	Closed	-$121K	–	1976
2019 Q1	$121K	Buy	22,384 +8,970	+67%	+$43.6K	0.01%	1103
2018 Q4	$40K	Buy	+13,414	New	+$73.5K	﹤0.01%	1299

Virtu Financial's ZYNE Position: Q4 2023 in Review

Virtu Financial sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2023, closing a stake of 13,098 shares — an estimated $17K sold.

Virtu Financial first reported a position in ZYNE in Q4 2018 and held it in 6 quarters. The position peaked at $170K in Q3 2019. 0 funds tracked by Wall St. Rank hold ZYNE as of Q4 2023.

Virtu Financial reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2023 after selling out during the quarter.
Virtu Financial sold 13,098 Zynerba Pharmaceuticals, Inc shares in Q4 2023, an estimated $17K.
Virtu Financial first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2018 and held it in 6 quarters.
Virtu Financial's Zynerba Pharmaceuticals, Inc position peaked at $170K in Q3 2019.
0 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2023.

Based on Virtu Financial's 13F filing for Q4 2023, filed 26 Feb 2024.